A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-08-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics,
immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and
in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer,
ovarian cancer, pancreatic cancer and gastric cancer.